Spark Therapeutics, Inc.
Gene therapy for inherited retinal diseases and other genetic disorders
- Sector
- Biotech
- Headquarters
- PHILADELPHIA, PA
- Founded
- 2013
- Latest Form D
- $72.8M, Jun 2014
- Total capital
- $72.8M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $72.8M
- 1 Form D · last Jun 2014
- 149 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 7
- 33 pending · first 2020
- Rank in peer group#213 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$72.8M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#213 · top 15%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Anand M. MehraDirectorNamed in SEC Form D filings
- Arthur M. DantchikDirectorNamed in SEC Form D filings
- Elliott M. SigalDirectorNamed in SEC Form D filings
- Jeffrey D. MarrazzoExecutive Officer, DirectorNamed in SEC Form D filings
- Joseph W. La BargeExecutive OfficerNamed in SEC Form D filings
- Lars M. Ekman, M.D. Ph.D.DirectorNamed in SEC Form D filings
Show all 8 people
- Rogerio M. VivaldiDirectorNamed in SEC Form D filings
- Steven M. AltschulerDirectorNamed in SEC Form D filings
What it has protected
USPTO · 7 granted of 40- PendingAdeno-associated Virus (aav) Vector Lipid Nanoparticle Compositions And Methods Of UseUSPTOApplication 19365082
- PendingGene Editing For Controlled Expression Of Episomal GenesUSPTOApplication 19119442
- PendingPiperazine CompoundsUSPTOApplication 19109760
Show all 40 patent records
- Adeno-associated Virus (aav) Vector Lipid Nanoparticle Compositions And Methods Of UseJul 30, 2026 · Application 19365082Pending
- Gene Editing For Controlled Expression Of Episomal GenesMay 7, 2026 · Application 19119442Pending
- Piperazine CompoundsMar 19, 2026 · Application 19109760Pending
- Adeno-associated Virus FormulationsDec 25, 2025 · Application 19246483Pending
- Relative Potency Assay For Viral Vector Encoding IsomerohydrolasesOct 2, 2025 · Application 19232675Pending
- Enhancing Non-viral Dna Delivery And ExpressionOct 2, 2025 · Application 19109831Pending
- ENHANCING AGENTS FOR IMPROVED CELL TRANSFECTION AND/OR rAAV VECTOR PRODUCTIONSep 2, 2025 · US 12,404,526Granted
- Immune Enhancement And Infectious Disease TreatmentJul 17, 2025 · Application 18853434Pending
- Relative Potency Assay For Viral Vector Encoding IsomerohydrolasesJul 15, 2025 · US 12,359,239Granted
- CpG REDUCED FACTOR VIII VARIANTS, COMPOSITIONS AND METHODS AND USES FOR TREATMENT OF HEMOSTASIS DISORDERSMay 29, 2025 · Application 18960905Pending
- Optimized Promoter Sequences, Intron-free Expression Constructs And Methods Of UseMay 6, 2025 · US 12,290,574Granted
- Codon-optimized Acid Alpha-glucosidase Expression Cassettes And Methods Of Using SameMar 27, 2025 · Application 18828493Pending
- Factor Viii (fviii) Gene Therapy MethodsMar 6, 2025 · Application 18803700Pending
- Method of Enhancing Gene Therapy by Targeting cGAS-STING PathwayOct 24, 2024 · Application 18685681Pending
- Compositions and Methods for Treating Fabry DiseaseSep 12, 2024 · Application 18261285Pending
- Codon-optimized Acid Alpha-glucosidase Expression Cassettes And Methods Of Using SameSep 10, 2024 · US 12,084,693Granted
- Aav Vector Column Purification MethodsAug 15, 2024 · Application 18568530Pending
- Compositions and Methods for Treating Hereditary AngioedemaApr 4, 2024 · Application 18262959Pending
- Methods Of Regulating Adeno-associated Virus ProductionMar 28, 2024 · Application 18535857Pending
- Methods of Enhancing Non-Viral Gene TherapyMar 7, 2024 · Application 18258981Pending
- Compositions And Methods For Increasing Or Enhancing Transduction Of Gene Therapy Vectors And For Removing Or Reducing ImmunoglobulinsAug 3, 2023 · Application 17759183Pending
- COLUMN-BASED FULLY SCALABLE rAAV MANUFACTURING PROCESSJul 18, 2023 · US 11,702,639Granted
- Compositions And Methods For Increasing Or Enhancing Transduction Of Gene Therapy Vectors And For Removing Or Reducing ImmunoglobulinsMay 11, 2023 · Application 17862622Pending
- Secretable Protein Induced Immune Tolerization And Treatment Of Autoimmune, Allergic And Other Diseases And DisordersFeb 9, 2023 · Application 17777954Pending
- Adeno-Associated Virus-Mediated CRISPR-Cas9 Treatment of Ocular DiseaseDec 8, 2022 · Application 17816367Pending
- Aav Vector Treatment Methods For Late Infantile Neuronal Ceroid Lipofuscinosis Type 2Jun 16, 2022 · Application 17310378Pending
- Plasmid Free Aav Vector Producing Cell LinesJan 27, 2022 · Application 17052097Pending
- In Vitro Assay For Detecting Enhancers And Inhibitors Of Adeno Associated Virus (aav) Vector Transduction And/or Detecting Or Quantitating Anti-aav Binding AntibodiesJan 13, 2022 · Application 17309261Pending
- Adeno-associated Virus (aav) Vector Lipid Nanoparticle Compositions And Methods Of UseDec 2, 2021 · Application 15733246Pending
- Engineered Aav Capsids With Increased Tropism For The Nucleus And Aav Vectors Comprising The Engineered Capsids And Methods Of Making And Using SameNov 25, 2021 · Application 17050362Pending
- CpG REDUCED FACTOR VIII VARIANTS, COMPOSITIONS AND METHODS AND USES FOR TREATMENT OF HEMOSTASIS DISORDERSNov 9, 2021 · US 11,168,124Granted
- Compositions And Methods For Increasing Or Enhancing Transduction Of Gene Therapy Vectors And For Removing Or Reducing ImmunoglobulinsAug 12, 2021 · Application 17224367Pending
- Compositions And Methods For Increasing Or Enhancing Transduction Of Gene Therapy Vectors And For Removing Or Reducing ImmunoglobulinsJul 29, 2021 · Application 17050911Pending
- Aav Vector Column Purification MethodsMar 18, 2021 · Application 16627227Pending
- Factor Viii (fviii) Gene Therapy MethodsJul 30, 2020 · Application 16635957Pending
- Apheresis Methods And UsesMay 28, 2020 · Application 16631692Pending
- Rab Escort Protein Potency AssayApr 28, 2020 · US 10,633,689Granted
- Scalable Methods For Producing Recombinant Adeno-associated Viral (aav) Vector In Serum-free Suspension Cell Culture System Suitable For Clinical UseSep 26, 2019 · Application 15780542Pending
- SCALABLE HIGH RECOVERY METHODS FOR PRODUCING HIGH YIELD RECOMBINANT ADENO-ASSOCIATED VIRAL (rAAV) VECTOR AND RECOMBINANT ADENO-ASSOCIATED VIRAL (rAAV) VECTORS PRODUCED THEREBYSep 19, 2019 · Application 16319216Pending
- Cell Line For Recombinant Protein And/or Viral Vector ProductionMar 14, 2019 · Application 16088693Pending
Related companies, and why
- Expansion TherapeuticsSimilar federal contract value in Biotech · null in contracts
- SepternaSimilar federal contract value in Biotech · null in contracts
- Blueprint MedicinesSimilar federal contract value in Biotech · null in contracts
- Kate TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Phosplatin Therapeutics Inc.Similar federal contract value in Biotech · null in contracts
- MYDNA, INCSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .